Advanced glycation end-product protein cross-links (AGE cross-links)

Advanced glycation end-product (AGE) protein cross-links are stable, covalent bonds formed non-enzymatically between reducing sugars and protein amino groups [1]. These modifications primarily affect long-lived structural proteins such as collagen, elastin, and lens crystallins, which have slow turnover rates [2]. AGEs accumulate progressively throughout the human lifespan, a process significantly accelerated by chronic hyperglycemia in diabetic patients [3]. The formation of these cross-links, particularly glucosepane, leads to the mechanical stiffening of the extracellular matrix and a loss of tissue elasticity [4]. This structural alteration is a primary driver of age-related pathologies, including systolic hypertension, arterial stiffness, and reduced joint mobility [5]. Beyond physical stiffening, AGEs interact with the Receptor for AGEs (RAGE) to trigger oxidative stress and chronic pro-inflammatory signaling [4]. Therapeutic interventions include "AGE breakers" like alagebrium, which are designed to chemically cleave these covalent bonds and restore tissue flexibility [5]. Other pharmacological approaches involve inhibitors like aminoguanidine that prevent the formation of reactive carbonyl intermediates before cross-linking occurs [1]. Modern research is increasingly focused on developing highly specific enzymes or small molecules capable of degrading glucosepane, the most abundant and clinically relevant AGE cross-link in humans [6].

Other names

AGEsMaillard reaction productsGlycation cross-linksGlucosepanePentosidineProtein-protein AGE cross-links

Pharmacological strategies include AGE breakers that cleave alpha-diketone bridges in existing cross-links, and AGE inhibitors that sequester reactive carbonyl intermediates to prevent cross-link formation.